Medical Press Release - Page 5 of 12 - Medika Life : Keeping you informed

Alterity has secured the worldwide exclusive right to patented technology to develop and commercialise therapies that re-sensitise bacteria to antibiotics

Voluntary Recall: Two Lots of NP Thyroid® Tablets, Due to Sub Potency

Medika Life - September 19, 2020

Acella Pharmaceuticals, LLC is voluntarily recalling one lot of 15-mg and one lot of 120-mg NP Thyroid®, Thyroid Tablets, USP [levothyroxine (T4) and liothyronine (T3)] to the consumer level.

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

Medika Life - August 12, 2020

SPRAVATO® (esketamine) CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

AI-Driven Model Supports Safer and More Precise Blood Sugar Management After Heart Surgery

Corundum Convergence Institute Launches to Catalyze Funding for Research and Innovation in Neuroscience and Systems Biology

StuffThatWorks and The Marfan Foundation to Engage in Pilot Program

Intellihealth Chief Medical Officer, Dr. Leon Igel, Honored as American Diabetes Association Greater New York Research Dinner Medical Honoree of the Year

LATEST

TRENDING

Medika’s Call for Food Aid for Starving Filipino Children

Lover, the App That Helps Women Reach Orgasm

ZEPOSIA® (ozanimod), a New Oral Treatment for Relapsing Forms of Multiple Sclerosis

The 50 Most Influential Leaders in Pharmacy 2022 Awards

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

FINN Partners Brings Aboard the Pharmacy Podcast Network

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

South University Announces New MSPA Program at West Palm Beach Campus

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

EDITORS CHOICE

FINN Partners Brings Aboard the Pharmacy Podcast Network

Alterity and UniQuest Partner to Reverse Bacterial Resistance to Antibiotics

Voluntary Recall: Two Lots of NP Thyroid® Tablets, Due to Sub Potency

SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults Approved

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories